Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
Background: Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are novel oral agents used for renal anemia treatment. Roxadustat, a first-in-class HIF-PHI used for treating anemia in chronic kidney disease patients, has been approved in China, Japan, South Korea, Chile, and Europe. Ro...
Shranjeno v:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Karger Publishers
2023-11-01
|
| Serija: | Kidney Diseases |
| Teme: | |
| Online dostop: | https://beta.karger.com/Article/FullText/535071 |
| Oznake: |
Brez oznak, prvi označite!
|